Xijie Yu

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4073588/publications.pdf

Version: 2024-02-01

		159585	85541
84	5,267	30	71
papers	citations	h-index	g-index

91	91	91	5487
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	FGF23 Actions in CKD-MBD and other Organs During CKD. Current Medicinal Chemistry, 2023, 30, 841-856.	2.4	1
2	Bone marrow adiposity during pathologic bone loss: molecular mechanisms underlying the cellular events. Journal of Molecular Medicine, 2022, 100, 167-183.	3.9	11
3	The Multiple Biological Functions of Dipeptidyl Peptidase-4 in Bone Metabolism. Frontiers in Endocrinology, 2022, 13, 856954.	3.5	6
4	Congenital insensitivity to pain with anhidrosis: A report of two unrelated Chinese families with novel mutations in NTRK1 gene. Medicina ClÃnica, 2021, 157, 451-453.	0.6	1
5	Articulation infection in patient with chronic granulomatous disease. Chinese Medical Journal, 2021, Publish Ahead of Print, 2492-2494.	2.3	0
6	Alcoholism and Osteoimmunology. Current Medicinal Chemistry, 2021, 28, 1815-1828.	2.4	10
7	Gut microbiota and bone metabolism. FASEB Journal, 2021, 35, e21740.	0.5	39
8	Pyogenic arthritis, pyoderma gangrenosum, and acne syndrome in a Chinese family: A case report and review of literature. World Journal of Clinical Cases, 2021, 9, 6393-6402.	0.8	0
9	Cellular senescence in knee osteoarthritis: molecular mechanisms and therapeutic implications. Ageing Research Reviews, 2021, 70, 101413.	10.9	62
10	Congenital insensitivity to pain with anhidrosis: A report of two unrelated Chinese families with novel mutations in NTRK1 gene. Medicina ClÃnica (English Edition), 2021, 157, 451-453.	0.2	0
11	Gut Microbiota and Serum Metabolic Signatures of High-Fat-Induced Bone Loss in Mice. Frontiers in Cellular and Infection Microbiology, 2021, 11, 788576.	3.9	19
12	A Chinese girl with mandibular hypoplasia, deafness, progeroid features, and lipodystrophy (MDPL) diagnosed via POLD1 mutation detection. Chinese Medical Journal, 2020, 133, 2009-2011.	2.3	8
13	Bone Marrow Adipocytes, Adipocytokines, and Breast Cancer Cells: Novel Implications in Bone Metastasis of Breast Cancer. Frontiers in Oncology, 2020, 10, 561595.	2.8	17
14	A novel JAG1 mutation causing Alagille syndrome presenting with giant hepatic nodules and discordant phenotype in monozygotic twins. Medicina ClÃnica (English Edition), 2020, 155, 507-509.	0.2	0
15	Bone marrow adipocytes enhance osteolytic bone destruction by activating 1q21.3(S100A7/8/9-IL6R)-TLR4 pathway in lung cancer. Journal of Cancer Research and Clinical Oncology, 2020, 146, 2241-2253.	2.5	11
16	A paternally inherited nonâ€sense variant c.424G>T (p.G142*) in the first exon of XLÎ±s in an adult patient with hypophosphatemia and osteopetrosis. Clinical Genetics, 2020, 97, 712-722.	2.0	3
17	Cellular Communication in Bone Homeostasis and the Related Anti-osteoporotic Drug Development. Current Medicinal Chemistry, 2020, 27, 1151-1169.	2.4	18
18	Management of bone metastasis with intravenous bisphosphonates in breast cancer: a systematic review and meta-analysis of dosing frequency. Supportive Care in Cancer, 2020, 28, 2533-2540.	2.2	17

#	Article	IF	Citations
19	The relationship between bone marrow adipose tissue and bone metabolism in postmenopausal osteoporosis. Cytokine and Growth Factor Reviews, 2020, 52, 88-98.	7.2	94
20	MicroRNA-17-92 Regulates Beta-Cell Restoration After Streptozotocin Treatment. Frontiers in Endocrinology, 2020, 11, 9.	3.5	12
21	Lung Cancer Cells Derived Circulating miR-21 Promotes Differentiation of Monocytes into Osteoclasts . OncoTargets and Therapy, 2020, Volume 13, 2643-2656.	2.0	15
22	Interleukin-6 Knockout Inhibits Senescence of Bone Mesenchymal Stem Cells in High-Fat Diet-Induced Bone Loss. Frontiers in Endocrinology, 2020, 11, 622950.	3.5	39
23	Interleukin-17A Interweaves the Skeletal and Immune Systems. Frontiers in Immunology, 2020, 11, 625034.	4.8	27
24	A novel JAG1 mutation causing Alagille syndrome presenting with giant hepatic nodules and discordant phenotype in monozygotic twins. Medicina ClÃnica, 2020, 155, 507-509.	0.6	1
25	Editorial: Novel Endocrine Functions of Bone Marrow Fat. Frontiers in Endocrinology, 2019, 10, 349.	3.5	0
26	A novel compound mutation in alpha-L-iduronidase gene causes mucopolysaccharidosis type I. Journal of Genetics, 2019, 98, 1.	0.7	0
27	Clinical implications of macrophage dysfunction in the development of osteoarthritis of the knee. Cytokine and Growth Factor Reviews, 2019, 46, 36-44.	7.2	82
28	The Unique Metabolic Characteristics of Bone Marrow Adipose Tissue. Frontiers in Endocrinology, 2019, 10, 69.	3.5	69
29	A novel heterozygous mutation c.680A>G (p. N227S) in SLC34A1 gene leading to autosomal dominant hypophosphatemia. Medicine (United States), 2019, 98, e15617.	1.0	2
30	A boy with mucopolysaccharidosis type II accompanied with a novel variation in heparan-N-sulfatase. Chinese Medical Journal, 2019, 132, 2254-2256.	2.3	1
31	The paradoxical coexistence of hypophosphatemic rickets and increased bone density in spine of a subject carrying a novel splice site mutation in PHEX. Chinese Medical Journal, 2019, 132, 2376-2377.	2.3	0
32	Skeletal-related adverse events during bone metastasis of breast cancer: current status. Discovery Medicine, 2019, 27, 211-220.	0.5	11
33	A novel compound mutation in alpha-L-iduronidase gene causes mucopolysaccharidosis type I. Journal of Genetics, 2019, 98, .	0.7	0
34	Bone turnover markers and novel biomarkers in lung cancer bone metastases. Biomarkers, 2018, 23, 518-526.	1.9	28
35	Ovariectomy-induced bone loss in TNFÎ± and IL6 gene knockout mice is regulated by different mechanisms. Journal of Molecular Endocrinology, 2018, 60, 185-198.	2.5	34
36	High Fructose and High Fat Exert Different Effects on Changes in Trabecular Bone Micro-structure. Journal of Nutrition, Health and Aging, 2018, 22, 361-370.	3.3	11

#	Article	IF	Citations
37	Bone Marrow Adipocyte: An Intimate Partner With Tumor Cells in Bone Metastasis. Frontiers in Endocrinology, 2018, 9, 339.	3.5	39
38	Interferon-Gamma-Mediated Osteoimmunology. Frontiers in Immunology, 2018, 9, 1508.	4.8	99
39	Novel Functions of MicroRNA-17-92 Cluster in the Endocrine System. Current Drug Targets, 2018, 19, 191-200.	2.1	9
40	A Review of the Clinical, Radiological and Biochemical Characteristics and Genetic Causes of High Bone Mass Disorders. Current Drug Targets, 2018, 19, 621-635.	2.1	5
41	Pro-inflammatory Cytokines: Cellular and Molecular Drug Targets for Glucocorticoid-induced-osteoporosis via Osteocyte. Current Drug Targets, 2018, 20, 1-15.	2.1	31
42	Effects of pulsed electromagnetic fields on postmenopausal osteoporosis. Bioelectromagnetics, 2017, 38, 406-424.	1.6	35
43	Fat, Sugar, and Bone Health: A Complex Relationship. Nutrients, 2017, 9, 506.	4.1	56
44	Pro-Inflammatory Cytokines: New Potential Therapeutic Targets for Obesity-Related Bone Disorders. Current Drug Targets, 2017, 18, 1664-1675.	2.1	30
45	Immune Cells Act as Promising Targets for the Treatment of Bone Metastasis. Recent Patents on Anti-Cancer Drug Discovery, 2017, 12, 221-233.	1.6	8
46	MicroRNAs in Osteoclastogenesis and Function: Potential Therapeutic Targets for Osteoporosis. International Journal of Molecular Sciences, 2016, 17, 349.	4.1	77
47	Enhanced but hypofunctional osteoclastogenesis in an autosomal dominant osteopetrosis type II case carrying a c.1856C>T mutation in CLCN7. Bone Research, 2016, 4, 16035.	11.4	16
48	High-Fat Diet Induces Distinct Metabolic Response in Interleukin-6 and Tumor Necrosis Factor-Î± Knockout Mice. Journal of Interferon and Cytokine Research, 2016, 36, 580-588.	1.2	12
49	Reduced femoral bone mass in both diet-induced and genetic hyperlipidemia mice. Bone, 2016, 93, 104-112.	2.9	27
50	MicroRNA-17-92 cluster regulates pancreatic beta-cell proliferation and adaptation. Molecular and Cellular Endocrinology, 2016, 437, 213-223.	3.2	35
51	Interleukin-6 gene knockout antagonizes high-fat-induced trabecular bone loss. Journal of Molecular Endocrinology, 2016, 57, 161-170.	2.5	19
52	Lipid metabolism disorders and bone dysfunction-interrelated and mutually regulated (Review). Molecular Medicine Reports, 2015, 12, 783-794.	2.4	63
53	Preservation of high-fat diet-induced femoral trabecular bone loss through genetic target of TNF-Î±. Endocrine, 2015, 50, 239-249.	2.3	46
54	Bone Metastasis-Related MicroRNAs: New Targets for Treatment?. Current Cancer Drug Targets, 2015, 15, 716-725.	1.6	5

#	Article	IF	Citations
55	MicroRNAs in Lung Cancer and Lung Cancer Bone Metastases: Biomarkers for Early Diagnosis and Targets for Treatment. Recent Patents on Anti-Cancer Drug Discovery, 2015, 10, 182-200.	1.6	14
56	Osteocalcin is inversely associated with glucose levels in middleâ€aged Tibetan men with different degrees of glucose tolerance. Diabetes/Metabolism Research and Reviews, 2014, 30, 476-482.	4.0	12
57	MiR-335 Inhibits Small Cell Lung Cancer Bone Metastases via IGF-IR and RANKL Pathways. Molecular Cancer Research, 2014, 12, 101-110.	3.4	87
58	MicroRNA-17-92 cluster regulates osteoblast proliferation and differentiation. Endocrine, 2014, 45, 302-310.	2.3	69
59	MicroRNA-204 critically regulates carcinogenesis in malignant peripheral nerve sheath tumors. Neuro-Oncology, 2012, 14, 1007-1017.	1.2	56
60	A novel animal model for bone metastasis in human lung cancer. Oncology Letters, 2012, 3, 802-806.	1.8	9
61	Bone Delivers Its Energy Information to Fat and Islets Through Osteocalcin. Orthopaedic Surgery, 2012, 4, 114-117.	1.8	7
62	Hyperactivation of mTOR critically regulates abnormal osteoclastogenesis in neurofibromatosis type 1. Journal of Orthopaedic Research, 2012, 30, 144-152.	2.3	17
63	Loss-of-function of SHARPIN causes an osteopenic phenotype in mice. Endocrine, 2011, 39, 104-112.	2.3	16
64	Double suicide genes driven by kinase domain insert containing receptor promoter selectively kill human lung cancer cells. Genetic Vaccines and Therapy, 2011, 9, 6.	1.5	6
65	Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, E1146-55.	7.1	318
66	MicroRNAâ€10b regulates tumorigenesis in neurofibromatosis type 1. Cancer Science, 2010, 101, 1997-2004.	3.9	88
67	Loss-of-function of SHARPIN causes an osteopenic phenotype in mice. Bone, 2010, 47, S398.	2.9	0
68	Skeletal abnormalities in neurofibromatosis type 1: Approaches to therapeutic options. American Journal of Medical Genetics, Part A, 2009, 149A, 2327-2338.	1.2	128
69	Molecular genetic and biochemical analyses of FGF23 mutations in familial tumoral calcinosis. American Journal of Physiology - Endocrinology and Metabolism, 2008, 295, E929-E937.	3.5	52
70	Molecular Insights into the Klotho-Dependent, Endocrine Mode of Action of Fibroblast Growth Factor 19 Subfamily Members. Molecular and Cellular Biology, 2007, 27, 3417-3428.	2.3	457
71	A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis. Journal of Clinical Investigation, 2007, 117, 2684-2691.	8.2	390
72	Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nature Genetics, 2006, 38, 1310-1315.	21.4	1,063

#	Article	IF	Citations
73	Neurofibromatosis Type 1 Gene Haploinsufficiency Reduces AP-1 Gene Expression without Abrogating the Anabolic Effect of Parathyroid Hormone. Calcified Tissue International, 2006, 78, 162-170.	3.1	10
74	Hyperactivation of p21ras and PI3K cooperate to alter murine and human neurofibromatosis type 1â€“haploinsufficient osteoclast functions. Journal of Clinical Investigation, 2006, 116, 2880-2891.	8.2	118
75	Fibroblast Growth Factor 23 and Its Receptors. Therapeutic Apheresis and Dialysis, 2005, 9, 308-312.	0.9	31
76	A Novel Recessive Mutation in Fibroblast Growth Factor-23 Causes Familial Tumoral Calcinosis. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 2424-2427.	3.6	205
77	Analysis of the Biochemical Mechanisms for the Endocrine Actions of Fibroblast Growth Factor-23. Endocrinology, 2005, 146, 4647-4656.	2.8	192
78	Neurofibromin and its inactivation of Ras are prerequisites for osteoblast functioning. Bone, 2005, 36, 793-802.	2.9	108
79	Mutations that Cause Osteoglophonic Dysplasia Define Novel Roles for FGFR1 in Bone Elongation. American Journal of Human Genetics, 2005, 76, 361-367.	6.2	295
80	FGF23 and disorders of phosphate homeostasis. Cytokine and Growth Factor Reviews, 2005, 16, 221-232.	7.2	113
81	Genetic dissection of phosphate- and vitamin D-mediated regulation of circulating Fgf23 concentrations. Bone, 2005, 36, 971-977.	2.9	141
82	The role of interleukin-6 and tumor necrosis factor alpha gene in fat and bone communication. Bone Abstracts, 0, , .	0.0	0
83	Signaling network of mirnas regulating bone metastasis in lung cancer. Bone Abstracts, 0, , .	0.0	0
84	Lung Cancer Derived Circulating miR-21 Promotes Bone Metastasis by Activating Differentiation of Monocytes to Osteoclasts. SSRN Electronic Journal, 0, , .	0.4	0